Elite in Malaria

Dr. Sara A. Healy

Pediatric Infectious Disease | Pediatrics
1155 Mill St, 5th Fl, Sierra Tower, 
Reno, NV 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Elite in Malaria
1155 Mill St, 5th Fl, Sierra Tower, 
Reno, NV 
OverviewInsuranceLocationsClinical Research

Overview

Sara Healy is a Pediatric Infectious Disease specialist and a Pediatrics provider in Reno, Nevada. Dr. Healy is rated as an Elite provider by MediFind in the treatment of Malaria. Her top area of expertise is Malaria. Dr. Healy is currently accepting new patients.

Her clinical research consists of co-authoring 46 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 41 articles and participated in 6 clinical trials in the study of Malaria.

Specialties
Pediatric Infectious Disease
Pediatrics
Licenses
Pediatric Infectious Diseases in ID
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
PacificSource
  • PPO

Locations

1155 Mill St, 5th Fl, Sierra Tower, Reno, NV 89502
Other Locations
4800 Sand Point Way NE, M/s R-5441, Seattle, WA 98105
305 E Jefferson St, Boise, ID 83712

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Screening of Healthy Volunteers for Investigational Antimalarial Drugs, Malaria Vaccines, and Controlled Human Malaria Challenge
Screening of Healthy Volunteers for Investigational Antimalarial Drugs, Malaria Vaccines, and Controlled Human Malaria Challenge
Enrollment Status: Recruiting
Publish Date: September 30, 2025
Phase 1 Dose Escalating, Double-Blind, Randomized Comparator Controlled Trial of the Safety andImmunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum at Full and Fractional Dosing in Adults in Mali
Phase 1 Dose Escalating, Double-Blind, Randomized Comparator Controlled Trial of the Safety andImmunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum at Full and Fractional Dosing in Adults in Mali
Enrollment Status: Completed
Publish Date: December 10, 2024
Intervention Type: Biological, Other, Drug
Study Phase: Phase 1
Sanaria PfSPZ Challenge With Pyrimethamine Chemoprophylaxis (PfSPZ-CVac Approach): Phase 1 Dose Escalation Trial to Determine Safety and Development of Protective Efficacy After Exposure to Only Pre-erythrocytic Stages of Plasmodium Falciparum
Sanaria PfSPZ Challenge With Pyrimethamine Chemoprophylaxis (PfSPZ-CVac Approach): Phase 1 Dose Escalation Trial to Determine Safety and Development of Protective Efficacy After Exposure to Only Pre-erythrocytic Stages of Plasmodium Falciparum
Enrollment Status: Completed
Publish Date: June 01, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 1
Dose Escalating and Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) in Healthy African Adults in Mali
Dose Escalating and Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) in Healthy African Adults in Mali
Enrollment Status: Completed
Publish Date: April 21, 2021
Intervention Type: Drug, Other, Biological
Study Phase: Phase 1
Phase 1 Study of the Safety and Immunogenicity of Pfs230D1M-EPA/Alhydrogel and Pfs25M-EPA/Alhydrogel, a Transmission Blocking Vaccine Against Plasmodium Falciparum Malaria in Adults in the US and Mali
Phase 1 Study of the Safety and Immunogenicity of Pfs230D1M-EPA/Alhydrogel and Pfs25M-EPA/Alhydrogel, a Transmission Blocking Vaccine Against Plasmodium Falciparum Malaria in Adults in the US and Mali
Enrollment Status: Completed
Publish Date: April 11, 2019
Intervention Type: Biological, Drug
Study Phase: Phase 1
Impact of Antimalarial Treatment on Measures of T Cell Suppression/Regulation in Healthy Adults From Ouelessebougou, Mali
Impact of Antimalarial Treatment on Measures of T Cell Suppression/Regulation in Healthy Adults From Ouelessebougou, Mali
Enrollment Status: Completed
Publish Date: June 14, 2018
View 5 Less Clinical Trials

46 Total Publications

A Vaccine to Block Plasmodium falciparum Transmission.
A Vaccine to Block Plasmodium falciparum Transmission.
Journal: NEJM evidence
Published: June 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Healy's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile